U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ho C, Spry C. Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 17.

Cover of Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines

Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet].

Show details

References

1.
Yates M, Watts R. ANCA-associated vasculitis. Clin Med (Lond) [Internet]. 2017 Feb [cited 2017 Apr 20];17(1):60-4. Available from: http://www.clinmed.rcpjournal.org/content/17/1/60.full.pdf+html. [PMC free article: PMC6297586] [PubMed: 28148583]
2.
Vasculitis types. In: About vasculitis [Internet]. Toronto: Vasculitis Foundation Canada; 2017 [cited 2017 May 3]. Available from: http://www.vasculitis.ca/?page_id=68.
3.
Randall KL. Rituximab in autoimmune diseases. Aust Prescr [Internet]. 2016 Aug [cited 2017 Apr 19];39(4):131-4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993704/pdf/austprescr-39-131.pdf.
4.
Moog P, Thuermel K. Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Ther Clin Risk Manag [Internet]. 2015 [cited 2017 Apr 19];11:1749-58. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669915/pdf/tcrm-11-1749.pdf. [PMC free article: PMC4669915] [PubMed: 26664125]
5.
Besada E, Nossent JC. CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients. PeerJ [Internet]. 2016 [cited 2017 Apr 19];4:e2487. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036106/pdf/peerj-04-2487.pdf. [PMC free article: PMC5036106] [PubMed: 27688979]
6.
Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) [Internet]. 2015 Jul [cited 2017 Apr 20];54(7):1153-60. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473766/pdf/keu452.pdf. [PMC free article: PMC4473766] [PubMed: 25477054]
7.
Calich AL, Puechal X, Pugnet G, London J, Terrier B, Charles P, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener’s). Results of a single-center cohort study on 66 patients. J Autoimmun. 2014 May;50:135–141. [PubMed: 24703438]
8.
Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum. 2012 Nov;64(11):3770–3778. [PubMed: 22730028]
9.
Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014 Oct;53(10):1818–1824. [PubMed: 24831059]
10.
Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim ALE, Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012 Jan;39(1):125–130. [PubMed: 22089465]
11.
Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness [Internet]. Ottawa: CADTH; 2015 Jan 28. [cited 2017 Apr 20]. (Rapid response report: summary with critical appraisal). Available from: https://www.cadth.ca/sites/default/files/pdf/htis/feb- 2015/RC0631%20Rituximab%20for%20GPA%20or%20MPA%20Final.pdf.
Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK482000
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (273K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...